SLC5A2 and heart failure: In one meta‐analysis, the use of SGLT2 inhibitors in older adults with diabetes reduced the risk of three‐point major adverse cardiovascular events (MACE), stroke, heart failure, and composite renal endpoints by 13, 17, 38, and 43%, respectively.77